Latest news with #ChibaUniversity
Business Wire
4 days ago
- Health
- Business Wire
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder
LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, shares positive results from a clinical study published in the peer-reviewed journal Aging Cell, by a team led by Masaya Koshizaka, M.D., Ph.D., Associate Professor, and Koutaro Yokote, M.D., Ph.D., MBA, President of Chiba University, both of the Center for Preventive Medical Sciences, Chiba University, and the Department of Diabetes, Metabolism and Endocrinology, Chiba University Hospital, Japan. This is the first study to demonstrate the safety and efficacy of Niagen Bioscience's patented nicotinamide riboside (NR) ingredient, Niagen ®, in individuals with Werner syndrome (WS), a rare genetic disorder marked by rapid aging and premature mortality. Niagen Bioscience Announces First Peer-Reviewed Study on NAD+ Supplement, Nicotinamide Riboside (NR), in Werner Syndrome Published by Niagen Bioscience Share The newly published double-blind, placebo-controlled study found that daily supplementation with Niagen significantly elevated blood NAD+ levels by approximately 140% and improved multiple clinical markers of cardiovascular and skin health in individuals with WS. Affecting approximately 1 in 380,000 to 1 in 1,000,000 people globally (GeneReviews), Werner syndrome is caused by mutations that impair DNA repair, leading to cellular aging decades ahead of normal progression. Dr. Koshizaka noted, 'We hope our work will accelerate studies on not only WS but also other premature aging disorders and common age-related diseases—ultimately helping to extend health span and improve quality of life in both patients and the broader population.' Developing NAD+ Therapies for Rare, Age-Related Diseases This study builds on the growing body of clinical research demonstrating Niagen's potential in rare, age-related diseases (see Table 1 below). In Ataxia Telangiectasia (AT), Niagen has shown improvements in neurological function, coordination, and immune markers, including in pediatric populations. Rob Fried, CEO of Niagen Bioscience, stated, 'Rare disease research is a priority for Niagen Bioscience, particularly those indications associated with accelerated aging, mitochondrial dysfunction, or NAD+ deficiency.' The U.S. Food and Drug Administration (FDA) previously granted Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation to NR for the treatment of AT. These designations underscore the urgent unmet need and potential therapeutic value of Niagen in rare disease populations. Why NAD+ Matters in Rare Disease Scientific research has shown that declining NAD+ levels can contribute to age-related decline, mitochondrial dysfunction, and impaired DNA repair. In both Werner syndrome and AT, NAD+ deficiency appears to play a central role in disease progression (Fang et al., 2019). By restoring NAD+ levels, Niagen may help activate protective enzymes like SIRT1 and PARP1, reduce oxidative stress, and improve tissue function (Fang et al., 2016; Veenhuis et al., 2021; Presterud et al., 2023; Shoji et al., 2025; Lautrup et al., 2025). Vilhelm Bohr, M.D., Ph.D., former National Institute on Aging (NIA) Chief of the Laboratory of Molecular Genetics, and current Affiliate Professor in Genome Instability and Neurodegeneration at the University of Copenhagen and Scientific Advisor to Niagen Bioscience and coauthor on the study, commented, 'Werner syndrome is a rare genetic disorder that has long served as a valuable model for understanding the mechanisms of human aging. This study marks the first clinical trial using Niagen in those with Werner syndrome, and the findings—particularly improvements in cardiovascular markers—are promising. As Werner syndrome is a well-established model for normal aging, these results also suggest that NAD+ supplementation may support healthier aging in the broader population.' Study Highlights This 52-week randomized, double-blind, placebo-controlled crossover trial evaluated the safety and efficacy of oral Niagen supplementation in individuals with WS. The study randomized nine individuals (mean age: 47) who received 1,000 mg/day of Niagen or placebo for 26 weeks before crossing over to the alternate treatment for an additional 26 weeks. Key findings include: Robust increase in NAD+ levels: Niagen supplementation led to a ~140% increase in plasma NAD+ levels, compared to a ~4% decrease in the placebo group. Improved arterial stiffness: Niagen significantly improved cardio-ankle vascular index (CAVI), a measure of arterial stiffness. Cardioprotective lipid shift: Niagen increased the number of large HDL particles, indicating potential cardiovascular benefits. Wound healing support: Niagen reduced skin ulcer size and heel pad thinning, while ulcers worsened in the placebo group. Clinical safety profile: No moderate or severe adverse events were reported. Mild adverse events were fewer in individuals who received Niagen (7) compared to those who received placebo (12). Tolerability in complex individuals: Although mild liver enzyme elevations were noted, they were deemed manageable and consistent with underlying liver sensitivities common in Werner syndrome. This study represents the first clinical evaluation of Niagen in WS and supports further investigation of NAD+ augmentation as a therapeutic strategy in rare progeroid diseases. For additional information on the science supporting Niagen ®, visit Table 1 The table below provides an overview of the clinical research published to date on Niagen in rare age-related conditions. About Niagen Bioscience: Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality. Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age. At the heart of its clinically proven product portfolio is Niagen ® (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen Bioscience's robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at where copies of press releases, news, and financial information are regularly published. Forward Looking Statements: This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to infringement or non-infringement of intellectual property rights. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. Xx Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
Yahoo
4 days ago
- Health
- Yahoo
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder
Results demonstrated that nicotinamide riboside (NR) significantly elevated NAD+ levels and improved multiple clinical markers in people with Werner Syndrome Niagen Bioscience expands rare disease research portfolio, supporting further investigation of NAD+ augmentation with NR as a therapeutic strategy in rare progeroid diseases LOS ANGELES, June 09, 2025--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, shares positive results from a clinical study published in the peer-reviewed journal Aging Cell, by a team led by Masaya Koshizaka, M.D., Ph.D., Associate Professor, and Koutaro Yokote, M.D., Ph.D., MBA, President of Chiba University, both of the Center for Preventive Medical Sciences, Chiba University, and the Department of Diabetes, Metabolism and Endocrinology, Chiba University Hospital, Japan. This is the first study to demonstrate the safety and efficacy of Niagen Bioscience's patented nicotinamide riboside (NR) ingredient, Niagen®, in individuals with Werner syndrome (WS), a rare genetic disorder marked by rapid aging and premature mortality. The newly published double-blind, placebo-controlled study found that daily supplementation with Niagen significantly elevated blood NAD+ levels by approximately 140% and improved multiple clinical markers of cardiovascular and skin health in individuals with WS. Affecting approximately 1 in 380,000 to 1 in 1,000,000 people globally (GeneReviews), Werner syndrome is caused by mutations that impair DNA repair, leading to cellular aging decades ahead of normal progression. Dr. Koshizaka noted, "We hope our work will accelerate studies on not only WS but also other premature aging disorders and common age-related diseases—ultimately helping to extend health span and improve quality of life in both patients and the broader population." Developing NAD+ Therapies for Rare, Age-Related Diseases This study builds on the growing body of clinical research demonstrating Niagen's potential in rare, age-related diseases (see Table 1 below). In Ataxia Telangiectasia (AT), Niagen has shown improvements in neurological function, coordination, and immune markers, including in pediatric populations. Rob Fried, CEO of Niagen Bioscience, stated, "Rare disease research is a priority for Niagen Bioscience, particularly those indications associated with accelerated aging, mitochondrial dysfunction, or NAD+ deficiency." The U.S. Food and Drug Administration (FDA) previously granted Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation to NR for the treatment of AT. These designations underscore the urgent unmet need and potential therapeutic value of Niagen in rare disease populations. Why NAD+ Matters in Rare DiseaseScientific research has shown that declining NAD+ levels can contribute to age-related decline, mitochondrial dysfunction, and impaired DNA repair. In both Werner syndrome and AT, NAD+ deficiency appears to play a central role in disease progression (Fang et al., 2019). By restoring NAD+ levels, Niagen may help activate protective enzymes like SIRT1 and PARP1, reduce oxidative stress, and improve tissue function (Fang et al., 2016; Veenhuis et al., 2021; Presterud et al., 2023; Shoji et al., 2025; Lautrup et al., 2025). Vilhelm Bohr, M.D., Ph.D., former National Institute on Aging (NIA) Chief of the Laboratory of Molecular Genetics, and current Affiliate Professor in Genome Instability and Neurodegeneration at the University of Copenhagen and Scientific Advisor to Niagen Bioscience and coauthor on the study, commented, "Werner syndrome is a rare genetic disorder that has long served as a valuable model for understanding the mechanisms of human aging. This study marks the first clinical trial using Niagen in those with Werner syndrome, and the findings—particularly improvements in cardiovascular markers—are promising. As Werner syndrome is a well-established model for normal aging, these results also suggest that NAD+ supplementation may support healthier aging in the broader population." Study Highlights This 52-week randomized, double-blind, placebo-controlled crossover trial evaluated the safety and efficacy of oral Niagen supplementation in individuals with WS. The study randomized nine individuals (mean age: 47) who received 1,000 mg/day of Niagen or placebo for 26 weeks before crossing over to the alternate treatment for an additional 26 weeks. Key findings include: Robust increase in NAD+ levels: Niagen supplementation led to a ~140% increase in plasma NAD+ levels, compared to a ~4% decrease in the placebo group. Improved arterial stiffness: Niagen significantly improved cardio-ankle vascular index (CAVI), a measure of arterial stiffness. Cardioprotective lipid shift: Niagen increased the number of large HDL particles, indicating potential cardiovascular benefits. Wound healing support: Niagen reduced skin ulcer size and heel pad thinning, while ulcers worsened in the placebo group. Clinical safety profile: No moderate or severe adverse events were reported. Mild adverse events were fewer in individuals who received Niagen (7) compared to those who received placebo (12). Tolerability in complex individuals: Although mild liver enzyme elevations were noted, they were deemed manageable and consistent with underlying liver sensitivities common in Werner syndrome. This study represents the first clinical evaluation of Niagen in WS and supports further investigation of NAD+ augmentation as a therapeutic strategy in rare progeroid diseases. For additional information on the science supporting Niagen®, visit Table 1The table below provides an overview of the clinical research published to date on Niagen in rare age-related conditions. Publication Dose Duration Health Area Study Design Key Outcomes Shoji et al., 2025 1000 mg 52 weeks Werner syndrome Randomized, double-blind, placebo-controlled crossover study in 11 individuals with Werner syndrome ~140% increase in plasma NAD+ levels; improved arterial stiffness and reduced skin ulcer size. No moderate or severe adverse events reported. Presterud et al., 2023 500 mg 2 years Ataxia Telangiectasia (AT) Open-label, single-arm observational study in 10 AT individuals Significant improvements in motor coordination and eye movements. No serious adverse events. Longest NR supplementation trial to date. Veenhuis et al., 2021 25 mg/kg 4 months Ataxia Telangiectasia (AT) Open-label proof-of-concept study in 24 AT individuals Improved ataxia scores (SARA, ICARS); effects reversed after withdrawal. Increased IgG levels in immunodeficient individuals. Tinnevelt et al., 2020 25 mg/kg 4 months Ataxia Telangiectasia (AT) Comparative study in 14 individuals with AT NR-related pathways and metabolites significantly increased following NR supplementation. About Niagen Bioscience: Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality. Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age. At the heart of its clinically proven product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen Bioscience's robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at where copies of press releases, news, and financial information are regularly published. Forward Looking Statements: This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to infringement or non-infringement of intellectual property rights. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. Xx Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. View source version on Contacts Niagen Bioscience Media Contact: Kendall Knysch, Senior Director of Media Relations & Niagen Bioscience Investor Relations Contact: ICR, LLCReed Anderson(646) 277-1260Stephanie Carrington(646) 277-1282niagenir@
Asahi Shimbun
27-05-2025
- Business
- Asahi Shimbun
Chiba's Afghan community blooms as more move overseas
YOTSUKAIDO, Chiba Prefecture—A plate of yellow long-grained rice makes its way over to a table at the restaurant Arian, with its cumin and coriander-infused aroma as equally vibrant as the dish. Afghanistan, long regarded as the 'crossroads of civilization' and bearing the less flattering association with its history of civil wars and invasions by major powers, is among the countries where biryani is a familiar sight. The dish is the flavorful result of stir-frying and slow-cooking a hodgepodge of ingredients and seasonings into a comforting dish most commonly found in South Asia and the Middle East. To order a plate at Arian or other entrees from India or Nepal, however, first means traveling about an hour by train and bus outside of Tokyo to the restaurant in Yotsukaido, Chiba Prefecture. The city is home to 1,200 Afghans who comprise 30 percent of its non-Japanese residents. Walking along a prefectural road lined by a drugstore and large retailers, one may occasionally come across women in hijab. Run by an Iranian man, Arian is not only a place that offers food from home—it doubles as a place to pick up groceries with a shop area stocked with meat and other halal ('permitted' in Arabic) food products with Muslim customers in mind. NOTHING TO FEAR The evening brings a stream of Afghans to the shop after they get off work. Most appear to work for automobile dismantlers or used car exporters in the neighborhood. Tomoko Fukuda, an associate professor of global sociology at Chiba University well-versed in economic activities of immigrants, said the foundations for what would grow into Yotsukaido's Afghan community were laid in the 1980s. The city's lower land prices and easy accessibility via an expressway encouraged many auto dismantlers to relocate there from Tokyo where real estate was already notoriously expensive. Some entrepreneurs in Afghanistan were starting businesses importing and selling used parts from Japanese cars around the same time. As Afghanistan's civil war intensified in the 1990s, a growing number of citizens began seeking new lives abroad, with Japan being one possible option. Yotsukaido is said to have been singled out because the concentration of vehicle dismantlers in the Japanese municipality made it an ideal place to buy in auto components. More recently, the city's Afghan population has risen 1.7-fold since the Islamist extremist group the Taliban took control of Kabul in 2021 after all U.S. troops withdrew from Afghanistan. Some at the shop said relatives working in the used car industry helped them with the moving process and obtaining business-related visas. Mohammad Abbas Ghulam Ali, 20, is a newcomer who relocated from his hometown of Kabul to Japan in January 2024. He now works at a used car export company founded by his older brother. Anime drew him in as a child, making Ali no stranger to 'Naruto,' 'One Piece' and other popular series that he watched online. 'Coming to Japan someday had long been a cherished dream of mine,' Ali said, eyes shining. 'I would like to live here permanently and become an actor or model at some point.' Ramazan, 33, who works at another used car company, said he secured a visa thanks to a friend who arrived ahead of him and works at the same company. 'Taliban members killed former government officials (from 2021 or beforehand) and abducted their families,' said Ramazan. 'My homeland was in danger.' In recounting why he came all the way to Yotsukaido, Ramazan touched on his experience in the country. 'I have nothing to fear here in Japan,' he said. 'I enjoy a sense of freedom, too. I want to continue my life in this place forever.' MOTIVATED STUDENTS Even with a sunnier outlook, some challenges still remain. 'We have few opportunities to master the Japanese language,' said Ramazan. 'My hope is to smoothly communicate with Japanese.' Children of non-Japanese parents are immersed in the language daily at school, but adults, busy with work and child-rearing, have limited chances to learn the language. To address this issue, the Cross-Cultural Association in Yotsukaido holds Japanese language classes three times a week. Association members and volunteer instructors are local citizens and most of the roughly 90 students registered are from Afghanistan. To accommodate religious practices and other needs that make it difficult for Afghan women to study in the same room as men, two of the three weekly lessons are women-only. One such class recently took place at a dedicated space in the city's general welfare center where students wore hijabs in a variety of colors, including blue, black and deep crimson. A stroller was also spotted. With textbooks open and ready, teachers provided students with one-on-one guidance and posed questions such as, 'How many lunch boxes did you prepare (for family members) today?' or 'What did you eat for breakfast this morning?' According to Hidetoshi Kojima, the 77-year-old president of the Cross-Cultural Association, those in the women-only class have a range of motivations for learning Japanese. Some are struggling to keep up with their children's conversations as their Japanese proficiency grows at school. Others intend to help with homework, only to find that the Japanese used in educational materials is too difficult for them to decipher. While a highly motivated student reportedly walks as long as 40 minutes to attend the course, this might be seen as a minor inconvenience considering warfare and that the Taliban prevents women from pursuing regular education in Afghanistan. For example, the Taliban has barred girls junior high school-age or older from enrolling in school. Atsuko Himeno, 75, has catered to students in the voluntary educational program for nearly 10 years. On one occasion, she accompanied an Afghan woman not proficient in Japanese on a hospital visit. Her dedication has earned Himeno the affectionate nickname 'sensei' (teacher). 'Helping people is my motivation,' she said. 'I want them (foreign women) to live without anxieties in Japan, as they already went through tough times in their homelands.' A 33-year-old student in the course and mother of three lamented the educational limitations placed on women in Afghanistan. 'It is a kind of sorrow that girls cannot attend school,' she said. However, she grew determined when speaking on her time in Japanese class. 'Studying is my favorite thing, and I am grateful to my teachers,' she said.
